首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   13475篇
  免费   946篇
  国内免费   425篇
耳鼻咽喉   88篇
儿科学   168篇
妇产科学   146篇
基础医学   2658篇
口腔科学   136篇
临床医学   868篇
内科学   2211篇
皮肤病学   120篇
神经病学   975篇
特种医学   178篇
外国民族医学   1篇
外科学   849篇
综合类   1440篇
预防医学   844篇
眼科学   81篇
药学   2771篇
中国医学   351篇
肿瘤学   961篇
  2023年   123篇
  2022年   238篇
  2021年   338篇
  2020年   257篇
  2019年   223篇
  2018年   271篇
  2017年   312篇
  2016年   348篇
  2015年   430篇
  2014年   697篇
  2013年   1180篇
  2012年   663篇
  2011年   767篇
  2010年   680篇
  2009年   739篇
  2008年   839篇
  2007年   730篇
  2006年   709篇
  2005年   633篇
  2004年   542篇
  2003年   434篇
  2002年   395篇
  2001年   327篇
  2000年   245篇
  1999年   282篇
  1998年   220篇
  1997年   219篇
  1996年   175篇
  1995年   210篇
  1994年   172篇
  1993年   167篇
  1992年   111篇
  1991年   127篇
  1990年   113篇
  1989年   98篇
  1988年   87篇
  1987年   76篇
  1986年   55篇
  1985年   97篇
  1984年   80篇
  1983年   49篇
  1982年   47篇
  1981年   52篇
  1980年   35篇
  1979年   44篇
  1978年   35篇
  1977年   42篇
  1976年   22篇
  1974年   18篇
  1973年   23篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的分析慢性心力衰竭患者血清氨基末端B型脑钠肽前体(NT-proBNP)、超敏C反应蛋白(hypersensitive C-reactive protein, hs-CRP)和糖类抗原-125(carbohydrate antigen-125, CA-125)水平特征。方法选取2019年1月-2020年12月沈阳医学院附属第二医院心血管内科收治的82例慢性心力衰竭患者纳入观察组,选取同期进行健康体检的82例健康者纳入对照组。对比分析两组患者血清NT-pro BNP、hs-CRP和CA-125水平,以及观察组治疗前后和不同心功能分级患者血清NT-pro BNP、hs-CRP和CA125水平的差异,分析心功能分级与血清NT-pro BNP、hs-CRP和CA-125水平的关系。结果观察组治疗前血清NT-pro BNP、hs-CRP和CA-125水平高于对照组,差异均具有统计学意义(P<0.05)。观察组治疗后血清NT-pro BNP、hs-CRP和CA-125水平较治疗前降低,差异均具有统计学意义(P<0.05)。观察组心功能Ⅲ级和Ⅳ级患者的血清NT-pro BNP、hs-CRP和CA-125水平高于心功能Ⅰ级和Ⅱ级患者,差异均具有统计学意义(P<0.05)。Spearman相关性分析显示,NT-pro BNP、hs-CRP和CA-125水平与患者的心功能分级呈正相关。结论慢性心力衰竭患者血清NT-pro BNP、hs-CRP和CA-125表达水平高于健康人群,且这3项指标与患者心功能分级呈正相关,可作为慢性心力衰竭患者病情评估的潜在指标。  相似文献   
2.
地鳖中的纤溶活性蛋白是从地鳖中提取的具有抗栓及抗肿瘤作用的有效成分,其口服易被上消化道酶分解从而限制了应用。采用恒流泵滴制法开发地鳖纤溶活性蛋白时间/pH依赖口服结肠靶向微囊(EnpolypHaga fibrinolytic protein oral colon targeting microcapsules, CTM-EFP)。采用单因素实验和正交实验相结合的方法寻找到包封率为60.17 % ± 2.72 %、载药量为15.50 % ± 0.44 % 的最佳配方。扫描电子显微镜(SEM)显示微囊呈球形、表面光滑,在人工肠液中24 h的累积释放度为99.53 % ± 0.69 %,在人工胃液中24 h累积释放度为7.43 ± 1.04 %,通过时间/pH依赖达到结肠靶向作用。CTM-EFP在人工肠液中的体外释放曲线符合Korsmeyer方程,提示地鳖纤溶活性蛋白(EnpolypHaga fibrinolytic protein, EFP)是通过扩散和侵蚀机制结合释放的。CTM-EFP为EFP的口服给药提供了一种新的剂型,为EFP应用于临床提供参考。  相似文献   
3.
《Saudi Pharmaceutical Journal》2022,30(11):1572-1588
Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of a metabolic syndrome caused by excessive accumulation of fat in the liver. Orthosiphon stamineus also known as Orthosiphon aristatus is a medicinal plant with possible potential beneficial effects on various metabolic disorders. This study aims to investigate the in vitro inhibitory effects of O. stamineus on hepatic fat accumulation and to further use the computational systems pharmacology approach to identify the pharmacokinetic properties of the bioactive compounds of O. stamineus and to predict their molecular mechanisms against NAFLD. Methods: The effects of an ethanolic extract of O. stamineus leaves on cytotoxicity, fat accumulation and antioxidant activity were assessed using HepG2 cells. The bioactive compounds of O. stamineus were identified using LC/MS and two bioinformatics databases, namely the Traditional Chinese Medicine Integrated Database (TCMID) and the Bioinformatics Analysis Tool for the Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM). Pathway enrichment analysis was performed on the predicted targets of the bioactive compounds to provide a systematic overview of the molecular mechanism of action, while molecular docking was used to validate the predicted targets. Results: A total of 27 bioactive compounds corresponding to 50 potential NAFLD-related targets were identified. O. stamineus exerts its anti-NAFLD effects by modulating a variety of cellular processes, including oxidative stress, mitochondrial β-oxidation, inflammatory signalling pathways, insulin signalling, and fatty acid homeostasis pathways. O. stamineus is significantly targeting many oxidative stress regulators, including JNK, mammalian target of rapamycin (mTOR), NFKB1, PPAR, and AKT1. Molecular docking analysis confirmed the expected high affinity for the potential targets, while the in vitro assay indicates the ability of O. stamineus to inhibit hepatic fat accumulation. Conclusion: Using the computational systems pharmacology approach, the potentially beneficial effect of O. stamineus in NAFLD was indicated through the combination of multiple compounds, multiple targets, and multicellular components.  相似文献   
4.
5.
目的:研究鱼藤素(De)诱导SGC-7901胃癌细胞凋亡的其作用机制。方法:运用CCK-8细胞活力检测法考察不同浓度(10、20、40、60、80、100 mol/L)鱼藤素作用24、48 h对SGC-7901胃癌细胞的细胞毒性;将SGC-7901胃癌细胞分为对照组及20、40 mol/L鱼藤素药物组,给药作用24 h后,蛋白质印迹法检测p-AKTThr308、叉头框蛋白O1(FoxO1)、B淋巴细胞瘤-2基因(Bcl-2)等蛋白的表达水平;运用蛋白激酶B(AKT)基因转染使SGC-7901胃癌细胞中AKT过表达,然后给予20、40 mol/L鱼藤素给药作用24 h,以未用AKT基因转染的SGC-7901胃癌细胞作为对照组蛋白质印迹法检测p-AKTThr308、FoxO1、Bcl-2等蛋白的表达水平,实时荧光定量PCR(RT-qPCR)检测FoxO1、Bcl-2、Bax mRNA的表达水平。结果:不同浓度的鱼藤素对SGC-7901胃癌细胞均具有一定的细胞毒性;20、40 mol/L鱼藤素给药作用24 h能够显著降低SGC-7901胃癌细胞中p-AKTThr308、Bcl-2等蛋白的表达水平,升高FoxO1的表达水平;与对照组比较,AKT基因转染后,SGC-7901胃癌细胞中p-AKTThr308、Bcl-2等蛋白表达水平升高,FoxO1蛋白表达降低,与模型组比较,20、40 mol/L鱼藤素给药作用后能够降低p-AKTThr308、Bcl-2等蛋白的表达水平,降低Bcl-2 mRNA的表达水平,升高FoxO1及Bax的表达水平。结论:鱼藤素能够通过作用于AKT/FoxO1信号通路诱导胃癌细胞SGC-7901凋亡。  相似文献   
6.
目的 免疫检查点抑制剂中的程序性细胞死亡蛋白受体1(programmed cell death protein1,PD-1)抑制剂已被用于多种晚期肿瘤的治疗中,该研究旨在识别恶性黑色素瘤术后PD-1抑制剂单药辅助治疗患者早期疲劳发展轨迹及其影响因素。 方法 采用便利抽样法,选取2020年4月—2021年12月于河南省某三级肿瘤医院和吉林省某三级甲等医院肿瘤科住院的患者作为调查对象,采用癌症疲乏量表调查患者首次PD-1抑制剂治疗后1、2、3、4周后的疲乏现状,利用组基轨迹模型识别106例PD-1抑制剂单药辅助治疗患者早期疲劳症状发展轨迹,运用多元Logistic回归分析患者早期疲劳症状发展轨迹的影响因素。 结果 识别出“疲劳缓解组”和“疲劳升高组” 2种早期疲劳发展轨迹。单因素分析结果显示,各亚组在肿瘤部位、自理能力、休息后是否缓解、伴有其他免疫相关不良事件个数方面的差异均具有统计学意义(P<0.05)。多元Logistic回归分析结果显示,早期疲劳症状休息后缓解[RR=0.026,95%CI(0.004,0.179)]、不伴有其他免疫相关不良事件[RR=0.255,95%CI(0.181,0.361)]被归属为类型2“疲劳升高组”的可能性较小。 结论 恶性黑色素瘤术后患者PD-1抑制剂辅助治疗早期疲劳发展呈现不同的变化轨迹,护士应重视疲劳症状休息后不缓解、伴有其他免疫相关不良事件患者早期疲劳症状的评估和干预。  相似文献   
7.
The discovery of effective drugs for the treatment of neurodegenerative disorders (NDs) is a deadlock. Due to their complex etiology and high heterogeneity, progresses in the development of novel NDs therapies have been slow, raising social/economic and medical concerns. Nanotechnology and nanomedicine evolved exponentially in recent years and presented a panoply of tools projected to improve diagnosis and treatment. Drug-loaded nanosystems, particularly nanoparticles (NPs), were successfully used to address numerous drug glitches, such as efficacy, bioavailability and safety. Polymeric nanoparticles (PNPs), mainly based on polylactic-co-glycolic acid (PLGA), have been already validated and approved for the treatment of cancer, neurologic dysfunctions and hormonal-related diseases. Despite promising no PNPs-based therapy for neurodegenerative disorders is available up to date. To stimulate the research in the area the studies performed so far with polylactic-co-glycolic acid (PLGA) nanoparticles as well as the techniques aimed to improve PNPs BBB permeability and drug targeting were revised. Bearing in mind NDs pharmacological therapy landscape huge efforts must be done in finding new therapeutic solutions along with the translation of the most promising results to the clinic, which hopefully will converge in the development of effective drugs in a foreseeable future.  相似文献   
8.
《Molecular therapy》2022,30(2):519-533
  1. Download : Download high-res image (159KB)
  2. Download : Download full-size image
  相似文献   
9.
10.
BackgroundTo study the effect of WISP1 on lipopolysaccharide (LPS)-induced cell injury in 3T3-L1 adipocytes.MethodLentivirus was transiently transfected into log phase 3T3-L1 adipocytes, which were then treated with LPS at a concentration of 10 μg/mL for 24 h. The cells were divided into the following groups: group A (control, untreated cells); group B (LPS-treated cells); group C (GFP), cells transfected with lentivirus-containing GFP; group D (GFP+LPS), group C treated with LPS;group E (WISP1OE), cells transfected with lentivirus, group F (shNC+LPS), cells transfected with lentivirus-containing nshRNA treated with LPS; group G (shWISP1 +LPS), cells transfected with lentivirus-containing shRNA treated with LPS; group H (WISP1OE+LPS), group E treated with LPS; group I (WISP1OE+LPS+LY294002), group E treated with LPS followed by LY294002 for 24 h.ResultsWISP1 overexpression notably ameliorated cell apoptosis, accompanied with the increased expression of bcl-2, the decreased expressions of bax and cleaved-caspase-3, and promoted the release of inflammatory factors, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in LPS-treated 3T3-L1 adipocytes. WISP1 knockdown exhibited the opposite results. In addition, WISP1 stimulated Akt phosphorylation and reduced nuclear translocation of Fork head box protein O3 (FoxO3a) in 3T3-L1 adipocytes treated by LPS. The inhibition of the PI3K/Akt signaling pathway diminished the protective effect of WISP1.ConclusionWISP1 prevents 3T3-L1 adipocytes from being injured by LPS by regulating the PI3K/Akt pathway.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号